ArticleDiagnostic pathology2015
Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.
Article in Diagnostic pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Role of MicroRNA-124 as a Prognostic Factor in Multiple Neoplasms: A Meta-Analysis.Disease markers · 2019Pooled it
- Epigenetic Silencing of miR-124 Drives KITENIN Activation in Colorectal Cancer.Biomolecules & therapeutics · 2026Article
- Molecular interaction of human papilloma virus (HPV) with microRANs: insights into the development of cervical cancer and treatment approaches.Infectious agents and cancer · 2025Review
- Review
- Review
- Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?Discover oncology · 2022Article
- Preoperative Routine Laboratory Markers for Predicting Postoperative Recurrence and Death in Patients with Breast Cancer.Journal of clinical medicine · 2021Article
- Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer.Non-coding RNA · 2020Review
- Circulating MicroRNAs and Blood-Brain-Barrier Function in Breast Cancer Metastasis.Current pharmaceutical design · 2020Article
- Prognostic role of microRNAs in breast cancer: A systematic review.Oncotarget · 2019Article
- MicroRNA-124: An emerging therapeutic target in cancer.Cancer medicine · 2019Review
- Expression and correlation of miR-124 and miR-126 in breast cancer.Oncology letters · 2019Article
- Differential MicroRNA Expression between EGFR T790M and L858R Mutated Lung Cancer.Journal of pathology and translational medicine · 2018Article
- miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer.Scientific reports · 2018Article
- microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11.Molecular cancer · 2018Article
- Comprehensive Assessment of the Relationship Between MicroRNA-124 and the Prognostic Significance of Cancer.Frontiers in oncology · 2018Article
- MicroRNA-124-3p directly targets PDCD6 to inhibit metastasis in breast cancer.Oncology letters · 2018Article
- miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK.Molecular therapy. Nucleic acids · 2017Article
- microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.Oncology letters · 2017Article
- Inhibition of LHX2 by miR-124 suppresses cellular migration and invasion in non-small cell lung cancer.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNA-124 (miR-124) has been reported to be downregulated in breast cancer. However, its clinical significance and prognostic value in breast cancer have not been extensively studied.
methodsThe tissue expression levels of miR-124 were measured using quantitative real-time PCR in 133 breast cancer patients. The correlation between the miR-124 levels and the clinicopathological factors of the patients was also analyzed. Survival and Cox proportional-hazards regression analyses were performed to determine the correlation between miR-124 expression levels and prognosis in the patients.
resultsQuantitative real-time PCR analysis showed that miR-124 had lower expression in breast cancer specimens than that in matched adjacent normal breast tissues (0.39 ± 0.16 vs. 1.00 ± 0.39; P < 0.05). Low miR-124 expression level was significantly associated with advanced TNM stage (P = 0.011), lymph node metastasis (P = 0.012), and poorer pathological differentiation (P = 0.023). A significant difference was found that breast cancer patients with low miR-124 expression level had distinctly shorter overall survival than patients with high miR-124 expression level (63.8% vs. 35.2%, P = 0.03). Furthermore, multivariate analysis of the prognosis factors with a Cox proportional hazards model confirmed that low miR-124 expression was a significant independent predictor of poor survival in breast cancer (HR = 3.16, 95% CI: 1.79-9.13, P = 0.017).
conclusionThese findings proved that the decreased expression of miR-124 might be associated with tumor progression and poor prognosis in patients with breast cancer. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3752603721493544.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.